Literature DB >> 16794369

MEN1 family with a novel frameshift mutation.

V Nuzzo1, L Tauchmanová, A Falchetti, A Faggiano, F Marini, S Piantadosi, M L Brandi, L Leopaldi, A Colao.   

Abstract

Multiple endocrine neoplasm type 1 (MEN1) syndrome predisposes to the development of endocrine and non-endocrine tumors with an autosomal dominant pattern of inheritance. Different mutations have been found throughout the gene with a variable phenotype expression. The proband, a Caucasian man, was admitted to our department in 2001, at the age of 51 because of a 1-yr history of diarrhoea and hypertension. He reported a previous intestinal resection for bowel occlusion with a histological diagnosis of unspecified mesenchymal neoplasia. He had also undergone a left adrenalectomy for a large nonfunctioning adrenal adenoma. Subsequently, he had suffered from gastralgia and melena; a gastroduodenoscopy showed an erosive gastritis. His family history was negative for endocrine disorders. On physical examination, multiple abdominal cutaneous lipomas and facial angiofibromas were observed. Biochemical screening revealed a primary hyperparathyroidism and an increase in circulating levels of PRL, chromogranin-A, gastrin and glucagon. The whole body computed tomography (CT) scan, the 111In-octreotide scan and the pituitary magnetic resonance imaging (MRI) did not reveal any abnormality. The presence of small neuroendocrine tumors was suspected by a positron emission tomography uptake in the epigastric region. The endoscopic ultrasound revealed a pancreatic lesion sized 1.1 cm that is under evaluation. Direct DNA sequencing analysis of the proband MEN1 gene revealed the 579delG frameshift mutation in the exon 3. The genetic screening of the family revealed the same mutation in 3 out of 5 offspring. The biochemical screening revealed some features of the MEN1 syndrome in all three of them. In conclusion, a novel frameshift MEN1 mutation was found in kindred with an apparently negative family history. Our experience confirms that MEN1 syndrome is a complex and underestimated condition, unless specifically investigated by trained specialists.

Entities:  

Mesh:

Year:  2006        PMID: 16794369     DOI: 10.1007/BF03344129

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

Review 1.  Multiple endocrine neoplasia type 1.

Authors:  M L Brandi
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series.

Authors:  P Ferolla; A Falchetti; P Filosso; P Tomassetti; G Tamburrano; N Avenia; G Daddi; F Puma; R Ribacchi; F Santeusanio; G Angeletti; M L Brandi
Journal:  J Clin Endocrinol Metab       Date:  2005-02-15       Impact factor: 5.958

3.  The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.

Authors:  W Shi; K D Buchanan; C F Johnston; C Larkin; Y L Ong; R Ferguson; J Laird
Journal:  Clin Endocrinol (Oxf)       Date:  1998-03       Impact factor: 3.478

Review 4.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

5.  Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred.

Authors:  J R Burgess; J J Shepherd; V Parameswaran; L Hoffman; T M Greenaway
Journal:  J Clin Endocrinol Metab       Date:  1996-07       Impact factor: 5.958

6.  Adrenal involvement in multiple endocrine neoplasia type 1.

Authors:  Peter Langer; Kenko Cupisti; Detlef K Bartsch; Christoph Nies; Peter E Goretzki; Matthias Rothmund; Hans D Röher
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

7.  Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form.

Authors:  F Gibril; D J Venzon; J V Ojeaburu; S Bashir; R T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

Review 8.  Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance.

Authors:  Matthew J Glascock; Sally E Carty
Journal:  Surg Oncol       Date:  2002-11       Impact factor: 3.279

Review 9.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

Review 10.  Molecular pathology of the MEN1 gene.

Authors:  Sunita K Agarwal; A Lee Burns; Karen E Sukhodolets; Patricia A Kennedy; Victor H Obungu; Alison B Hickman; Michael E Mullendore; Ira Whitten; Monica C Skarulis; William F Simonds; Carmen Mateo; Judy S Crabtree; Peter C Scacheri; Youngmi Ji; Elizabeth A Novotny; Lisa Garrett-Beal; Jerrold M Ward; Steven K Libutti; H Richard Alexander; Aniello Cerrato; Michael J Parisi; Sonia Santa Anna-A; Brian Oliver; Settara C Chandrasekharappa; Francis S Collins; Allen M Spiegel; Stephen J Marx
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

View more
  5 in total

1.  Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.

Authors:  Francesca Marciello; Carolina Di Somma; Michela Del Prete; Vincenzo Marotta; Valeria Ramundo; Annachiara Carratù; Chiara de Luca di Roseto; Luigi Camera; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2014-01-03       Impact factor: 3.633

2.  Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database.

Authors:  Francesca Marini; Francesca Giusti; Caterina Fossi; Federica Cioppi; Luisella Cianferotti; Laura Masi; Francesca Boaretto; Stefania Zovato; Filomena Cetani; Annamaria Colao; Maria Vittoria Davì; Antongiulio Faggiano; Giuseppe Fanciulli; Piero Ferolla; Diego Ferone; Paola Loli; Franco Mantero; Claudio Marcocci; Giuseppe Opocher; Paolo Beck-Peccoz; Luca Persani; Alfredo Scillitani; Fabiana Guizzardi; Anna Spada; Paola Tomassetti; Francesco Tonelli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2018-03-01       Impact factor: 3.633

3.  Silent familial isolated pituitary adenomas: histopathological and clinical case report.

Authors:  C Villa; F Magri; P Morbini; A Falchetti; P Scagnelli; E Lovati; D Locatelli; F R Canevari; V Necchi; E Gabellieri; G Guabello; L Chiovato; E Solcia
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  Genetic variation and its role in malignancy.

Authors:  Bente A Talseth-Palmer; Rodney J Scott
Journal:  Int J Biomed Sci       Date:  2011-09

5.  TIO Associated with Hyperparathyroidism: A Rarity, a Rule, or a Novel HPT-PMT Syndrome-A Case Study with Literature Review.

Authors:  Michael Salim; Mohannad Samy Behairy; Elena Barengolts
Journal:  Case Rep Endocrinol       Date:  2021-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.